赎回负债及优先股上市时转股

19.52亿元附优先权股份将于上市时转换

As of April 30, 2023, we recorded RMB1,952.3 million in financial instruments issued to investors, which were attributable to the shares with preferential rights we issued to the Pre-IPO Investors and contributed to our net current liability position historically.

Financial Information · 第 529 页

Such shares will be converted into ordinary Shares upon Listing, after which they will no longer be recorded as current liabilities on our statement of financial position.

Financial Information · 第 529 页

A substantial portion of such costs are not expected to continue after Listing, as (i) all of our borrowings from Kelun Pharmaceutical had been fully settled as of the Latest Practicable Date, of which RMB2.5 billion was settled by way of debt-to-equity swap and the remaining was settled by cash; and (ii) the Shares we issued to Series A Investors will be converted into ordinary Shares upon Listing.

Financial Information · 第 504 页

优先股等金融负债按FVTPL计量并于上市时转股

We recorded these financial instruments as financial liabilities at FVTPL for which no quoted prices in an active market exist.

Financial Information · 第 280 页

We expect to return to net asset position upon Listing, taking into account the re-designation of the convertible redeemable preferred shares with carrying amount of RMB2,984.4 million as of December 31, 2022 from financial liabilities to equity as a result of the automatic conversion into ordinary Shares.

Business · 第 195 页